Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Stage III Lung Adenocarcinoma

Known as: Stage III Adenocarcinoma of Lung, Stage III Lung Adenocarcinoma AJCC v7, Stage III Adenocarcinoma of the Lung 
Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB… Expand
National Institutes of Health

Related topics

Related topics

27 relations
ALK geneChestChromosome 13q deletionCoughing
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Use of 18F-FDG PET/CT to predict short-term outcomes early in the course of chemoradiotherapy in stage III adenocarcinoma of the lung.
The purpose of the present prospective study was to evaluate the use of 18F-fluorodeoxyglucose positron emission tomography… Expand
  • table I
  • table II
  • figure 1
Is this relevant?
2017
2017
Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein encoded by a gene located in the short arm of chromosome… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2016
2016
Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001)
The objective of this phase 2 trial was to assess the efficacy and safety of induction bevacizumab plus chemotherapy followed by… Expand
Is this relevant?
2016
2016
A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
BackgroundConcurrent chemotherapy and radiation is the standard treatment for unresectable stage III Lung adenocarcinoma. However… Expand
  • table 1
  • table 2
  • table 4
  • table 3
  • figure 1
Is this relevant?
2016
2016
Whole exome sequencing analysis of the neoadjuvant bevacizumab plus pemetrexed and carboplatin for unresectable stage III lung adenocarcinoma: Results of the phase II GASTO 1001 trial.
e20045Background: GASTO 1001 is a phase II trial investigating the efficacy and safety of induction bevacizumab plus chemotherapy… Expand
Is this relevant?
2015
2015
Phase II trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
7528 Background: Unresectable stage III non-small cell lung cancer is often treated with concurrent chemoradiotherapy… Expand
Is this relevant?
2014
2014
The impact of EGFR mutation on definitive concurrent chemoradiation therapy for inoperable stage III lung adenocarcinoma.
7558 Background: Concurrent chemoradiation therapy (CRT) is the current standard of care for patients with locally advanced lung… Expand
Is this relevant?
2012
2012
Recruitment of Podoplanin Positive Cancer-Associated Fibroblasts in Metastatic Lymph Nodes Predicts Poor Prognosis in Pathological N2 Stage III Lung Adenocarcinoma
BackgroundCancer-associated fibroblasts (CAFs) directly communicate with cancer cells and play important roles in cancer… Expand
  • figure 1
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Review
2012
Review
2012
Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: Carcinoembryonic antigen as a potential predictive factor
The predictive factors for the development of brain metastases in patients with stage III non‐small‐cell lung cancer receiving… Expand
Is this relevant?
1988
1988
Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.
Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test 
  • figure 1
  • table I
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE